These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 9707298)
1. Relationship of gender and menstrual status to symptoms and medication side effects in patients with schizophrenia. Magharious W; Goff DC; Amico E Psychiatry Res; 1998 Feb; 77(3):159-66. PubMed ID: 9707298 [TBL] [Abstract][Full Text] [Related]
2. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771 [TBL] [Abstract][Full Text] [Related]
3. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients. Faraone SV; Brown WA; Laughren TP J Clin Psychiatry; 1987 Apr; 48(4):151-4. PubMed ID: 2881923 [TBL] [Abstract][Full Text] [Related]
4. Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients. Csernansky JG; Kaplan J; Holman CA; Hollister LE Psychopharmacology (Berl); 1983; 81(2):115-8. PubMed ID: 6138793 [TBL] [Abstract][Full Text] [Related]
5. Menstrual cycle characteristics in women with persistent schizophrenia. Gleeson PC; Worsley R; Gavrilidis E; Nathoo S; Ng E; Lee S; Kulkarni J Aust N Z J Psychiatry; 2016 May; 50(5):481-7. PubMed ID: 26070315 [TBL] [Abstract][Full Text] [Related]
6. Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance. Sumiyoshi T; Hasegawa M; Jayathilake K; Meltzer HY Biol Psychiatry; 1997 Mar; 41(5):560-6. PubMed ID: 9046988 [TBL] [Abstract][Full Text] [Related]
7. Serum iron abnormalities in neuroleptic-induced akathisia in schizophrenic patients. Soni SD; Tench D; Routledge RC Br J Psychiatry; 1993 Nov; 163():669-72. PubMed ID: 7905347 [TBL] [Abstract][Full Text] [Related]
8. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Goff DC; Henderson DC; Amico E Am J Psychiatry; 1992 Sep; 149(9):1189-94. PubMed ID: 1503131 [TBL] [Abstract][Full Text] [Related]
9. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Szymanski S; Lieberman JA; Alvir JM; Mayerhoff D; Loebel A; Geisler S; Chakos M; Koreen A; Jody D; Kane J Am J Psychiatry; 1995 May; 152(5):698-703. PubMed ID: 7726309 [TBL] [Abstract][Full Text] [Related]
10. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Canuso CM; Goldstein JM; Wojcik J; Dawson R; Brandman D; Klibanski A; Schildkraut JJ; Green AI Psychiatry Res; 2002 Aug; 111(1):11-20. PubMed ID: 12140115 [TBL] [Abstract][Full Text] [Related]
11. Gender-related clinical differences in older patients with schizophrenia. Lindamer LA; Lohr JB; Harris MJ; McAdams LA; Jeste DV J Clin Psychiatry; 1999 Jan; 60(1):61-7; quiz 68-9. PubMed ID: 10074884 [TBL] [Abstract][Full Text] [Related]
12. Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial. Malik P; Kemmler G; Hummer M; Riecher-Roessler A; Kahn RS; Fleischhacker WW; J Clin Psychopharmacol; 2011 Jun; 31(3):274-80. PubMed ID: 21508850 [TBL] [Abstract][Full Text] [Related]
13. Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Bergemann N; Mundt C; Parzer P; Jannakos I; Nagl I; Salbach B; Klinga K; Runnebaum B; Resch F Schizophr Res; 2005 Mar; 73(2-3):357-66. PubMed ID: 15653282 [TBL] [Abstract][Full Text] [Related]
14. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone. Kopala LC; Fredrikson D; Good KP; Honer WG Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777 [No Abstract] [Full Text] [Related]
15. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Breier AF; Malhotra AK; Su TP; Pinals DA; Elman I; Adler CM; Lafargue RT; Clifton A; Pickar D Am J Psychiatry; 1999 Feb; 156(2):294-8. PubMed ID: 9989566 [TBL] [Abstract][Full Text] [Related]
16. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Gur RE; Maany V; Mozley PD; Swanson C; Bilker W; Gur RC Am J Psychiatry; 1998 Dec; 155(12):1711-7. PubMed ID: 9842780 [TBL] [Abstract][Full Text] [Related]
17. Prolactin shifts after neuroleptic withdrawal. Green AI; Faraone SV; Brown WA Psychiatry Res; 1990 Jun; 32(3):213-9. PubMed ID: 1975101 [TBL] [Abstract][Full Text] [Related]
18. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. Ghadirian AM; Chouinard G; Annable L J Nerv Ment Dis; 1982 Aug; 170(8):463-7. PubMed ID: 6124580 [TBL] [Abstract][Full Text] [Related]
19. Neuroleptic nonresponse and affective symptoms: a 2-year prospective study of schizophrenic outpatients. Faraone SV; Young AS; Brown WA Psychiatry Res; 1989 Jun; 28(3):315-21. PubMed ID: 2569751 [TBL] [Abstract][Full Text] [Related]
20. Neuroleptic dose and schizophrenic symptoms. A survey of prescribing practices. Peralta V; Cuesta MJ; Caro F; Martinez-Larrea A Acta Psychiatr Scand; 1994 Nov; 90(5):354-7. PubMed ID: 7872040 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]